Glutamine

Dosage for Glutamine is highly dependent on the specific condition being treated and, in many cases, the patient's body weight.

• Sickle Cell Disease (Endari): The standard adult dose is 5 grams to 15 grams taken orally twice daily. The specific dose is based on body weight:
• Less than 30 kg: 5 grams (1 packet) twice daily.
• 30 kg to 65 kg: 10 grams (2 packets) twice daily.
• Greater than 65 kg: 15 grams (3 packets) twice daily.
• Short Bowel Syndrome (NutreStore): The typical dose is 5 grams taken orally six times daily (for a total of 30 grams per day) for up to 16 weeks. This is often part of a specific regimen involving a specialized diet and potentially growth hormone injections.

• Sickle Cell Disease: Glutamine is FDA-approved for children aged 5 years and older. The weight-based dosing for pediatric patients follows the same guidelines as adults (5g to 15g twice daily based on weight tiers).
• Short Bowel Syndrome: Safety and efficacy have not been established in pediatric patients for SBS; use in this population is at the discretion of a specialist.

Renal Impairment

Specific dosage adjustments for renal impairment are not provided in the manufacturer's labeling. However, because glutamine metabolism generates urea and ammonia, healthcare providers should exercise caution in patients with severe renal failure to avoid nitrogenous waste buildup.

Hepatic Impairment

Glutamine should be used with extreme caution in patients with severe hepatic impairment. In patients with liver failure, the body cannot effectively process the ammonia produced during glutamine metabolism, which may lead to or worsen hepatic encephalopathy (brain dysfunction due to liver failure).

Elderly Patients

Clinical trials did not include sufficient numbers of patients over 65 to determine if they respond differently. In general, dose selection should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.

Glutamine oral powder must be mixed with food or liquid before ingestion. It should not be swallowed as a dry powder.

• Mixing: Mix the powder with 8 ounces (240 mL) of a cold or room-temperature beverage (such as water, milk, or apple juice) or 4 to 6 ounces of food (such as applesauce or yogurt).
• Temperature: Do not mix with hot liquids or hot foods, as heat can degrade the amino acid.
• Timing: The powder does not need to be completely dissolved; a "gritty" texture is normal. Drink or eat the entire mixture immediately.
• Storage: Store the packets at room temperature (68°F to 77°F). Keep them away from moisture and direct sunlight.

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not double the dose to catch up, as this may increase the risk of gastrointestinal side effects.

Acute overdose of glutamine is unlikely to be life-threatening, as it is a naturally occurring amino acid. However, very high doses may lead to significant gastrointestinal distress, including severe nausea, vomiting, and diarrhea. In patients with underlying liver or kidney disease, an overdose could potentially lead to elevated ammonia levels. If an overdose is suspected, contact a Poison Control Center or seek emergency medical attention immediately.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking Glutamine without medical guidance, as this could lead to a recurrence of sickle cell complications or malabsorption issues.

In clinical trials for sickle cell disease, the most frequently reported adverse reactions occurred in more than 10% of patients. These include:

• Constipation: This is the most common side effect. Patients may experience infrequent bowel movements or difficulty passing stool. This is often manageable with increased fluid intake or fiber, but you should consult your doctor before using laxatives.
• Nausea: A feeling of sickness in the stomach. This is usually mild and often subsides if the medication is taken with a meal.
• Headache: Mild to moderate headaches may occur, particularly when starting the medication.
• Abdominal Pain: General discomfort or cramping in the stomach area. This is frequently related to the volume of powder being ingested.
• Cough: Some patients report a persistent dry cough.
• Extremity Pain: Pain in the arms or legs, which can sometimes be confused with a mild sickle cell crisis.

• Back Pain: A dull ache in the lower or upper back.
• Chest Pain (Non-Cardiac): Discomfort in the chest area that is not related to heart issues.
• Pruritus: Itching of the skin without a visible rash.
• Flatulence: Increased gas and bloating, often occurring shortly after taking the dose.

• Splenic Infarction: While rare, some patients with sickle cell disease may experience issues with the spleen. It is unclear if this is caused by the drug or the underlying disease.
• Hypersensitivity Reactions: Rare instances of skin rashes or localized swelling.

> Warning: Stop taking Glutamine and call your doctor immediately if you experience any of these symptoms:

• Signs of an Allergic Reaction: Hives, difficulty breathing, or swelling of your face, lips, tongue, or throat (Anaphylaxis).
• Severe Abdominal Pain: Intense, sharp pain in the abdomen that does not go away, which could indicate a more serious gastrointestinal issue.
• Jaundice: Yellowing of the eyes or skin, which may indicate liver stress, especially in those with pre-existing hepatic conditions.
• Altered Mental Status: Confusion, extreme drowsiness, or disorientation, which could be a sign of hyperammonemia (excess ammonia in the blood) in patients with liver disease.

Glutamine is generally considered safe for long-term use when prescribed by a healthcare provider. However, long-term high-dose supplementation may potentially affect the balance of other amino acids in the blood. In patients with sickle cell disease, the primary goal is long-term reduction in crises, and studies lasting up to 48 weeks have shown a consistent safety profile. There is no evidence currently suggesting that long-term use leads to organ toxicity in patients with normal organ function.

No FDA black box warnings have been issued for Glutamine as of 2026. It is considered to have a favorable safety profile compared to other treatments for sickle cell disease, such as hydroxyurea, which carries warnings regarding bone marrow suppression.

Report any unusual symptoms or side effects that persist to your healthcare provider. You may also report side effects to the FDA at 1-800-FDA-1088.

Glutamine is a medical-grade product and should be used only under the supervision of a healthcare professional. It is not a substitute for other treatments but rather an additive therapy in most clinical protocols. Patients must ensure they are using the specific brand or formulation prescribed by their doctor, as different products (e.g., Endari vs. NutreStore) have different mixing instructions and intended uses.

There are currently no FDA black box warnings for Glutamine. Unlike many other medications used for chronic conditions, glutamine does not have a high risk of life-threatening toxicity in the general population for which it is indicated.

• Hepatic Impairment and Hyperammonemia: This is the most significant clinical precaution. Glutamine is metabolized into ammonia. In patients with liver failure or urea cycle disorders, the body cannot clear this ammonia. This can lead to hyperammonemia, which causes brain swelling and neurological damage. If you have a history of liver disease or cirrhosis, your doctor must monitor you closely.
• Renal Function: Patients with end-stage renal disease (ESRD) or significant kidney impairment may have difficulty processing the nitrogen load associated with high-dose amino acid therapy. Monitoring of Blood Urea Nitrogen (BUN) is essential.
• Allergic Reactions: While glutamine is a natural substance, the inactive ingredients in the powder or the manufacturing process can cause hypersensitivity in rare cases.

If you are taking Glutamine for a chronic condition, your healthcare provider will likely order periodic blood tests, including:

• Liver Function Tests (LFTs): To ensure the liver is processing the amino acid load correctly.
• Renal Function Tests (Creatinine/BUN): To monitor kidney health.
• Complete Blood Count (CBC): To track the progress of sickle cell disease management.

Glutamine is not known to cause drowsiness or cognitive impairment. It is generally safe to drive or operate machinery while taking this medication. However, if you experience headaches or dizziness as a side effect, wait until these symptoms resolve before performing tasks that require full alertness.

There is no direct chemical interaction between glutamine and alcohol. However, chronic alcohol use can damage the liver. Since the liver is responsible for metabolizing glutamine and clearing ammonia, heavy alcohol consumption may increase the risk of side effects or reduce the drug's efficacy. It is best to limit alcohol intake while on this therapy.

Glutamine does not cause physical dependence, and there is no known withdrawal syndrome. However, in patients with sickle cell disease, stopping the medication abruptly may lead to an increase in the frequency of painful crises. Always consult your doctor before stopping the medication to ensure a safe transition to alternative therapies if needed.

> Important: Discuss all your medical conditions, especially liver or kidney disease, with your healthcare provider before starting Glutamine.

There are no absolute contraindications for drug-drug combinations with glutamine; however, it should never be used in patients with a known hypersensitivity to L-glutamine or any component of the formulation.

• Lactulose: Lactulose is used to lower ammonia levels in patients with liver disease. Because glutamine metabolism produces ammonia, taking high doses of glutamine may theoretically reduce the effectiveness of lactulose. If both are necessary, ammonia levels must be monitored strictly.
• Anticonvulsants (e.g., Valproic Acid, Phenobarbital): Some anti-seizure medications can affect ammonia levels or are metabolized in ways that involve the glutamate-glutamine cycle in the brain. Glutamine may potentially lower the seizure threshold in susceptible individuals, though this is rare.

• Chemotherapeutic Agents: There is ongoing research regarding glutamine and cancer. Some studies suggest it protects healthy cells from chemo-toxicity, while others suggest it could theoretically provide fuel for certain types of tumor cells. If you are undergoing cancer treatment, consult your oncologist before using glutamine.
• NMDA Receptor Antagonists (e.g., Memantine): Since glutamine is a precursor to glutamate (an excitatory neurotransmitter that acts on NMDA receptors), there is a theoretical pharmacodynamic interaction. The clinical significance of this is currently unknown.

• Hot Foods and Liquids: Glutamine is heat-sensitive. Mixing the powder with hot coffee, tea, or cooked oatmeal will cause the amino acid to break down, rendering the dose ineffective. Always use cold or room-temperature vehicles for administration.
• High-Protein Diets: Since glutamine is an amino acid, a diet extremely high in protein may increase the total nitrogen load on the kidneys. No specific restrictions are usually required, but balance is key.

• Other Amino Acids: Taking large amounts of single amino acids (like arginine or lysine) alongside glutamine may lead to competition for transport across the intestinal wall, potentially reducing the absorption of glutamine.
• St. John's Wort: No known interaction, but always inform your doctor of any herbal supplements.

• Ammonia Levels: Glutamine will naturally cause a transient rise in plasma ammonia levels. This is usually not clinically significant in healthy individuals but can complicate the interpretation of lab results in patients with liver disease.
• BUN (Blood Urea Nitrogen): High doses of glutamine may slightly increase BUN levels as the body processes the extra nitrogen.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking to avoid potential complications.

• Hypersensitivity: Glutamine must NEVER be used in patients with a documented life-threatening allergy to L-glutamine or any of the excipients in the pharmaceutical preparation. Anaphylaxis, though rare, is a contraindication for further use.
• Severe Hepatic Encephalopathy: Because the liver cannot clear the ammonia produced by glutamine metabolism, giving glutamine to a patient in an active state of hepatic encephalopathy can worsen brain swelling and potentially lead to coma or death.

• Severe Renal Failure: In patients with a GFR (Glomerular Filtration Rate) less than 30 mL/min, the kidneys may struggle to excrete the urea generated from glutamine. A risk-benefit analysis is required, and lower doses may be necessary.
• Bipolar Disorder or Mania: There are isolated reports suggesting that high doses of glutamine might trigger manic episodes in predisposed individuals due to its role as a precursor to glutamate, an excitatory neurotransmitter. Use with caution in psychiatric populations.
• Active Malignancy: As mentioned in the interactions section, some tumors are "glutamine-dependent." While not an absolute contraindication, use in cancer patients requires specialist oncological oversight.

There is no known cross-sensitivity between glutamine and other common drug classes (like sulfonamides or penicillins). However, patients who have had reactions to other amino acid infusions or parenteral nutrition components should be monitored closely during their first few doses of oral glutamine.

> Important: Your healthcare provider will evaluate your complete medical history, including liver and kidney health, before prescribing Glutamine.

Glutamine is classified by the FDA as Pregnancy Category C (under the older system). There are no adequate and well-controlled studies of L-glutamine in pregnant women. Animal reproduction studies have not been conducted. However, glutamine is a naturally occurring amino acid required for fetal growth. The decision to use glutamine during pregnancy should be based on whether the potential benefit to the mother (e.g., preventing a sickle cell crisis) outweighs the potential risk to the fetus. It is especially important during the third trimester when fetal nutrient demands are highest.

Glutamine is a normal constituent of human milk. It is not known if supplemental pharmaceutical-grade glutamine significantly increases the concentration in breast milk or if it has any adverse effects on the nursing infant. Because many drugs are excreted in human milk, caution should be exercised. Most clinicians consider it compatible with breastfeeding, but monitoring the infant for gastrointestinal upset is advised.

Glutamine (as Endari) is specifically FDA-approved for use in pediatric patients 5 years of age and older for sickle cell disease. Safety and effectiveness in children under 5 have not been established. In the approved age group, the safety profile is similar to that of adults. There is no evidence that glutamine therapy negatively affects growth or development in children.

Clinical studies of glutamine did not include enough patients aged 65 and over to determine if they respond differently than younger patients. Because elderly patients are more likely to have decreased renal or hepatic function, healthcare providers usually perform baseline testing of kidney and liver function before starting therapy. Dose adjustments are not standard but should be considered if organ impairment is present.

In patients with mild to moderate renal impairment, glutamine is generally well-tolerated. In severe impairment or end-stage renal disease (ESRD), the nitrogen load from 30 grams of glutamine daily may be excessive. Dialysis patients may require timing of their dose around their dialysis sessions, as glutamine and its metabolites are water-soluble and cleared by dialysis.

Glutamine is contraindicated in patients with severe hepatic failure or encephalopathy. For those with mild to moderate hepatic impairment (Child-Pugh Class A or B), glutamine should be used with caution and frequent monitoring of blood ammonia levels. If signs of confusion or lethargy develop, the medication should be discontinued immediately.

> Important: Special populations require individualized medical assessment and frequent follow-up with a specialist.

Glutamine is a pleiotropic amino acid (having multiple effects). In sickle cell disease, it serves as a precursor for the synthesis of Nicotinamide Adenine Dinucleotide (NAD+ and NADH). These molecules are essential for maintaining the "redox potential" of red blood cells. By increasing the NAD+/NADH ratio, glutamine helps neutralize reactive oxygen species (ROS), thereby protecting the red blood cell membrane from oxidative damage. This reduces the likelihood of the cell becoming "sickled" and adhering to the vascular endothelium (vessel walls).

In the gut, glutamine acts as a primary respiratory fuel for rapidly dividing cells. It is utilized via the glutaminolysis pathway to produce ATP. It also regulates the expression of tight junction proteins, which are essential for maintaining the intestinal barrier and preventing "leaky gut" syndrome in SBS patients.

The pharmacodynamic effect of glutamine in sickle cell disease is not immediate. It typically takes several weeks of consistent dosing to alter the redox state of the RBC population sufficiently to see a reduction in crises. In SBS, the trophic effects on the bowel also occur over weeks to months of therapy.

| Parameter | Value |

|---|---|

| Bioavailability | Variable (Saturable transport) |

| Protein Binding | Minimal |

| Half-life | ~1 hour |

| Tmax | 0.5 - 2 hours |

| Metabolism | Hepatic/Renal/Intestinal (via Glutaminase) |

| Excretion | Primarily metabolic; <5% Renal (unchanged) |

• Molecular Formula: C5H10N2O3
• Molecular Weight: 146.14 g/mol
• Solubility: Soluble in water (35 g/L at 25°C); insoluble in ethanol.
• Structure: A five-carbon amino acid with a side-chain amide group, making it polar but uncharged at physiological pH.

Glutamine is categorized as an amino acid. In the context of sickle cell disease, it is considered a sickle cell anemia agent. It is distinct from cytotoxic agents like hydroxyurea or targeted antibodies like crizanlizumab.